Showing results (1-10 of 252) with videos related to
Sort By:
Pageof 26
Clinical Pharmacology and Therapeutics|September 6, 2012
Personalizing antiplatelet therapy with clopidogrelD Trenk, O Zolk, M F Fromm, et al.Thrombosis and Haemostasis|December 15, 2012
High on-treatment platelet reactivity and P2Y12 antagonists in clinical trialsD Trenk, S D Kristensen, W Hochholzer, et al.Clinical Pharmacology and Therapeutics|April 8, 2011
Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactionsO Zolk, M F FrommZeitschrift Fur Gastroenterologie|January 13, 2011
[Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology]T Rabenstein, M F Fromm, O ZolkThrombosis and Haemostasis|February 29, 2012
Micro-array profiling exhibits remarkable intra-individual stability of human platelet micro-RNAC Stratz, T G Nührenberg, H Binder, et al.Herz|November 21, 2018
[ESC/EACTS guidelines on myocardial revascularization 2018 : The most important innovations]F-J Neumann, W Hochholzer, M SiepeBritish Journal of Pharmacology|October 2, 2010
Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cationsJ König, O Zolk, K Singer, et al.Herz|October 1, 2014
[Clinical pharmacology of current antiplatelet drugs]D Trenk, T Nührenberg, C Stratz, et al.Biochemical and Biophysical Research Communications|July 7, 2009
Functionalized silicon quantum dots tailored for targeted siRNA deliveryS Klein, O Zolk, M F Fromm, et al.Clinical Pharmacology and Therapeutics|May 29, 2009
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatinJ E Keskitalo, O Zolk, M F Fromm, et al.Pageof 26